aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.
domingo, 31 de octubre de 2021
sábado, 30 de octubre de 2021
viernes, 29 de octubre de 2021
jueves, 28 de octubre de 2021
miércoles, 27 de octubre de 2021
martes, 26 de octubre de 2021
lunes, 25 de octubre de 2021
domingo, 24 de octubre de 2021
sábado, 23 de octubre de 2021
viernes, 22 de octubre de 2021
jueves, 21 de octubre de 2021
miércoles, 20 de octubre de 2021
Register Now: November 16 Webinar on Consumer Assessment of Healthcare Providers and Systems Patient Narrative Items
Webex Events (classic)
Registration is open for an AHRQ webinar on Nov. 16 from 1 to 2 p.m. ET to highlight the final Patient Narrative Item Set for the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician & Group Survey. The narrative set consists of open-ended questions that enable survey users to collect comments from patients about their healthcare experiences. In this webinar, CAHPS researchers will present the narrative items for both the 3.0 and 4.0 versions of the Clinician & Group Survey and answer questions about using them. They will also preview Narrative Item Sets in development for the CAHPS Health Plan Survey and the Child HCAHPS Survey.
martes, 19 de octubre de 2021
lunes, 18 de octubre de 2021
Notice of Updates | FDA
Notice of Updates | FDA
Notice of Updates – FDA Recognized Antimicrobial Susceptibility Test Interpretive Criteria
FDA Updates
FDA recognizes, as of October 14, 2021, with certain exceptions, the standards published in: Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.
Also, FDA recognizes in part the standards published in: Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Susceptibility Testing of Mycobacteria, Norcardia spp. and other Aerobic Actinomycetes. CLSI guideline M62- 1st Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
In addition, FDA updated recognition of the susceptibility test interpretive criteria (STIC) for azithromycin, cefazolin, cefiderocol, ceftolozane tazobactam, colistimethate, imipenem-cilastatin-relebactam, lefamulin, and polymyxin B. FDA has also removed telithromycin breakpoints as the drug has been withdrawn.
For additional information about the FDA susceptibility test interpretive criteria recognition please visit http://www.fda.gov/STIC.